Extended Bisphosphonate Treatment Does Not Improve Survival in High-Risk Early Breast Cancer
There was no benefit to extending zoledronate treatment beyond 2 years.
Breast Cancer News
BREAST CANCER ADVISOR
Breast Cancer News
Overcoming Obstacles to Health Equity in Breast Cancer Prevention and Control
The current scientific evidence may not be generalizable to underrepresented groups.
Factors ID’d for Radiologist Performance in Screening Mammography
Geographic location of radiology practice, breast subspecialization, performing diagnostic mammography tied to radiologist performance.
Disparities in Breast Cancer Survival Persist for Black Women
Although nearly all metrics improved for racial-ethnic minorities, recent breast cancer-related mortality in Florida still higher in Black women.
Trastuzumab Emtansine in Stage I HER2+ Breast Cancer
Among patients with stage I HER2+ breast cancer, adjuvant treatment with T-DM1 was associated with “excellent” 3-year iDFS, but was not associated with fewer clinically relevant toxicities compared with paclitaxel plus trastuzumab.
Ovarian Stimulation Drugs Not Tied to Higher Breast Cancer Risk
Use of clomiphene citrate or gonadotropins, alone or in combination, not associated with increased risk for breast cancer.
Pembrolizumab Does Not Confer Survival Benefit in Metastatic Triple-Negative Breast Cancer
Overall survival was similar with pembrolizumab and single-agent chemotherapy.
Women’s Cancer Screenings Plummeted During Pandemic
Decline especially noticeable among women of racial and ethnic minority groups with low incomes.
Racial Disparities in Survival Among Triple-Negative Breast Cancer Patients Partially Explained by Treatment Differences
The study showed differences in receipt of chemotherapy and surgery but not radiotherapy.
ASCO Updates Recommendations for Managing Hereditary Breast Cancer
Rapid recommendation provides updated guidance on the use of adjuvant olaparib.
Talazoparib Is Active in gBRCA1/2 Mutation-Positive, HER2-Negative Early Breast Cancer
Researchers evaluated the efficacy and safety of talazoparib in the neoadjuvant setting in a phase 2, nonrandomized, single-arm, open-label study.
On-Treatment Ki-67: A Promising Prognostic Marker for Early Breast Cancer Management
Dr Alan Lyss reviews results from the high-risk cohort of the WSG-ADAPT HR+/HER2- trial.
Public Interest in Cancer Screenings Decreased Early During the COVID-19 Pandemic
Researchers observed a “sharp” decline in public interest.
Adding Alpelisib to Fulvestrant Doesn’t Impact HRQOL in Advanced Breast Cancer
The overall treatment effect in global health status/quality of life was similar between the treatment arms.
ASCO and Friends: Cancer Patients Should Be Included in COVID-19 Vaccine Trials
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Breast Cancer Prognosis No Better With Five Versus Two Years of Zoledronate
No significant difference found in disease-free survival, overall survival, distant disease-free survival for five versus two years of treatment.
Closing the Gap Between Cancer Patients and Researchers: A Patient Advocate’s Perspective on GRASP
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
The Past, Present, and Future of GRASP: Connecting Cancer Researchers, Clinicians, and Patient Advocates
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
Use of Hypofractionated Radiotherapy in Breast Cancer Has More Than Doubled in Recent Years
The use of hypofractionated whole-breast irradiation increased significantly from 2004 to 2016.
‘High Frequency’ of Germline Mutations Found in Patients With Metastatic Breast Cancer
The mutation rate was significantly higher in metastatic breast cancer than in nonmetastatic breast cancer.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Breast Cancer News
Loading... 
Loading...